A Phase 1, Non-randomized, Open-label, Single Dose Study To Evaluate The Effect Of Renal Impairment On The Pharmacokinetics, Safety And Tolerability Of Rivipansel (Pf-06460031) In Subjects With Renal Impairment And In Healthy Subjects

Trial Profile

A Phase 1, Non-randomized, Open-label, Single Dose Study To Evaluate The Effect Of Renal Impairment On The Pharmacokinetics, Safety And Tolerability Of Rivipansel (Pf-06460031) In Subjects With Renal Impairment And In Healthy Subjects

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Sep 2017

At a glance

  • Drugs Rivipansel (Primary)
  • Indications Haematological malignancies; Sickle cell anaemia
  • Focus Adverse reactions; Pharmacokinetics
  • Sponsors Pfizer
  • Most Recent Events

    • 31 Aug 2017 Planned End Date changed from 1 Aug 2017 to 1 Nov 2017.
    • 31 Aug 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Nov 2017.
    • 03 Aug 2017 Planned End Date changed from 10 Aug 2017 to 1 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top